Bank of America Downgrades Novavax to Underperform Citing Long-Term Growth Concerns
Bank of America downgraded Novavax to Underperform due to concerns about the vaccine maker's sustainable growth prospects amid shifting COVID-19 variants and heightened FDA regulatory requirements.
Bank of America lowered its rating on Novavax to Underperform from Neutral, citing mounting questions about the vaccine maker's long-term growth prospects despite recent progress in stabilizing operations. The firm cut its price target to $7 from $9, reflecting growing skepticism about the company's ability to maintain momentum in a rapidly evolving post-pandemic market.
Analysts acknowledged that Novavax has executed well in recent quarters, slashing operating expenses by roughly two-thirds from pandemic-era highs and shoring up its balance sheet through significant cost-cutting measures. However, they warned that key growth drivers remain uncertain and the path to sustainable profitability appears increasingly narrow.
Demand for Novavax's COVID-19 shot, Nuvaxovid, is expected to fade as the vaccine targets the JN.1 variant, while the dominant strain in circulation is now NB.1.8.1. This mismatch between vaccine formulation and circulating strains creates significant challenges for the company's near-term revenue prospects. New clinical studies will likely be needed under the Food and Drug Administration's updated vaccine framework, which requires more rigorous—and costly—trials as new strains emerge.
The heightened regulatory bar could also complicate potential partnerships for Novavax's experimental COVID-19/influenza combination vaccine, the analysts said. While the company has enjoyed a short-term lift amid funding cuts to some mRNA rivals, Bank of America believes the outlook for sustainable growth is limited given the competitive landscape and regulatory hurdles.
Novavax shares have swung sharply this year as investors weigh the company's retrenchment efforts against a narrowing path for growth. The downgrade reflects broader concerns about the viability of standalone COVID-19 vaccine manufacturers as the market transitions from emergency pandemic response to seasonal vaccination programs with more stringent requirements.
The regulatory pressure from the FDA requiring larger, costlier trials represents a significant barrier to entry for new vaccine formulations, potentially limiting Novavax's ability to quickly adapt to evolving viral strains. This comes despite the company's impressive cost reduction achievements, having cut operating expenses by approximately 66% from peak levels during the pandemic.
The company's pipeline focus remains on its COVID-19/flu combination vaccine candidate, but the analysts expressed concerns about the commercialization potential given the challenging regulatory environment and competitive market dynamics. The downgrade underscores the difficult transition facing vaccine companies as they navigate the post-pandemic landscape where growth prospects appear increasingly constrained.